State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):221-233. doi: 10.1080/14737167.2021.1860022. Epub 2021 Jan 12.
: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors' objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches.: We conducted a systematic literature review of cost-effectiveness analysis (CEA) published up to 25 July 2020 in PubMed, web of science, and the ISPOR presentation database, compared once-weekly semaglutide with other GLP-1 RAs in T2D. Nineteen studies were identified, including 8 short-term and 11 long-term studies. General characteristics and main results of the included studies were summarized.: This review provided references for other countries to overview the value of once-weekly semaglutide compared with other GLP-1 RAs in T2D in the healthcare decision-making process and to conduct their CEA studies associated with once-weekly semaglutide. The authors found that the cardiovascular (CV) benefit of once-weekly semaglutide was under-estimated in current studies and suggested that the methods of economic evaluations for novel anti-diabetic drugs with CV benefit should be improved in future researches.
作为一种新型的胰高血糖素样肽-1 受体激动剂（GLP-1RA），用于治疗 2 型糖尿病（T2D），每周一次司美格鲁肽的经济学价值已在多个国家进行了评估。作者的目的是系统地回顾现有的药物经济学文献，评估每周一次司美格鲁肽与其他 GLP-1RA 相比的成本效益，并为进一步的研究提供启示。
我们在 PubMed、web of science 和 ISPOR 演示数据库中，对截至 2020 年 7 月 25 日发表的成本效益分析（CEA）进行了系统的文献回顾，比较了每周一次司美格鲁肽与 T2D 中的其他 GLP-1RA。确定了 19 项研究，包括 8 项短期研究和 11 项长期研究。总结了纳入研究的一般特征和主要结果。
这项综述为其他国家在医疗保健决策过程中，概述每周一次司美格鲁肽与其他 GLP-1RA 在 T2D 中的相对价值提供了参考，并开展了与每周一次司美格鲁肽相关的 CEA 研究。作者发现，目前的研究低估了每周一次司美格鲁肽的心血管（CV）获益，并建议在未来的研究中改进具有 CV 获益的新型抗糖尿病药物的经济评估方法。
